RxDoctor Payments Data

Purvi Patel, MD

Internal Medicine · Orland Park, ILNPI 1962689117

Payments from drug & device makers

$905in general payments, 2019–2025

Across 19 payments — averaging $47.65 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Teleflex LLC$262
  • Abbott$172
  • Lantheus Medical Imaging, Inc.$119
  • GSK$114
  • Novo Nordisk$103
  • Phadia US Inc.$28
  • plus $108 from 5 others

What the payments were for

  • Food & beverage$88097%
  • Education$253%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$905 in reported general payments places this provider in the 75th percentile of 5,182 internal medicine providers in Illinois.

See all internal medicine providers in Illinois

Medicare billing

Part B allowed, 2024
$158,948
Medicare patients
309
Services billed
3,421

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide181$213,659
EliquisApixaban115$108,417
JardianceEmpagliflozin71$87,762
TrulicityDulaglutide40$53,304
JanuviaSitagliptin Phosphate44$50,269
MounjaroTirzepatide40$41,053
RybelsusSemaglutide30$40,829
Trelegy ElliptaFluticasone/Umeclidin/Vilanter44$38,669
ProliaDenosumab20$35,326
WegovySemaglutide24$32,149
FarxigaDapagliflozin Propanediol26$31,779
Spiriva HandihalerTiotropium Bromide18$14,222
MyrbetriqMirabegron13$13,140
Tresiba Flextouch U-100Insulin Degludec18$12,520
ZenpepLipase/Protease/Amylase25$8,907

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic, Rybelsus, Wegovy$103$286,637235 claims
Boehringer IngelheimJardiance$18$87,76271 claims
MerckJanuvia$25$50,26944 claims
GSKTrelegy Ellipta, Arnuity Ellipta$114$42,84856 claims
AmgenProlia$16$35,32620 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 5,182 internal medicine providers in Illinois.

Other internal medicine in Orland Park

See the full list for Illinois

Where these figures come from

Is this you, or does something look wrong? →